EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Translate Bio's enterprise value is $2,214.6 Mil.
Translate Bio's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was $51.8 Mil. Therefore, Translate Bio's EV-to-EBITDA for today is 42.75.
The historical rank and industry rank for Translate Bio's EV-to-EBITDA or its related term are showing as below:
TBIO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.93 Med: -3.31 Max: 677.01
Current: 42.75
During the past 5 years, the highest EV-to-EBITDA of Translate Bio was 677.01. The lowest was -24.93. And the median was -3.31.
TBIO's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.1
vs TBIO: 42.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Translate Bio EV-to-EBITDA Historical Data
The historical data trend for Translate Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Translate Bio's EV-to-EBITDA
For the Biotechnology subindustry, Translate Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Translate Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Translate Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Translate Bio's EV-to-EBITDA falls into.
Translate Bio EV-to-EBITDA Calculation
Translate Bio's EV-to-EBITDA for today is calculated as:
Translate Bio's current Enterprise Value is $2,214.6 Mil.
Translate Bio's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $51.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Translate Bio (NAS:TBIO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Translate Bio's PE Ratio for today is calculated as:
Translate Bio's share price for today is $37.36.
Translate Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.506.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Translate Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Translate Bio (Translate Bio) Business Description
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBIO has been successfully added to your 